Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2019 | VIOLA: azacitidine and lenalidomide salvage therapy for AML

Charles Craddock • 26 Oct 2019
COSTEM 2019
Acute Myeloid Leukemia Leukemia Azacitidine Lenalidomide Venetoclax
VIOLA

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, University of Birmingham, Birmingham, UK, provides an outline of the key findings from his study on combination therapy of lenalidomide and azacitidine in salvage therapy of relapsed acute myeloid leukemia (AML) patients post-allogeneic stem cell transplantation. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

More from Charles Craddock

2:14
Addressing the high rate of disease relapse following alloSCT in patients with AML
Charles Craddock • 10 Dec 2023
1:32
Stem cell transplantation conditioning in AML: making the decision between MAC and RIC
Charles Craddock • 10 Dec 2023
1:22
The UK Impact Transplant Trials Network: a national strategy to accelerate delivery of alloSCT RCTs
Charles Craddock • 10 Dec 2023
Transplantation & immunotherapies
Charles Craddock et al. • 4 Sep 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals